cGAS-STING pathway

Overview

The cGAS-STING pathway, comprising cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) and stimulator of interferon genes (STING), is a crucial component of the innate immune response. This pathway is activated in response to the presence of cytosolic DNA, which can originate from pathogens or damaged host cells. Upon activation, cGAS synthesizes cyclic dinucleotides that bind to STING, leading to the activation of downstream signaling cascades that promote the production of type I interferons and other proinflammatory cytokines. This response plays a significant role in anti-tumor immunity, making the cGAS-STING pathway a promising target for cancer immunotherapy.

Recent Publications Summary

Recent publications continue to position the cGAS-STING pathway as a central node linking cytosolic DNA sensing, innate immune activation, and therapeutic response across inflammatory disease, cancer, and tissue injury. In autoimmune and inflammatory settings, a newly reported cGAS/HDAC dual inhibitor, 31h, directly suppressed cGAS activity while increasing cGAS acetylation through HDAC3 inhibition, and showed efficacy in murine models of inflammatory bowel disease and Aicardi-Goutières syndrome 42268702Jun. In diabetic retinopathy, elevated aqueous humor dsDNA, mitochondrial damage, and retinal pigment epithelial dysfunction were associated with retinal cGAS-STING activation, and STING inhibition reduced cytoplasmic dsDNA accumulation, damaged mitochondria, inflammation, and vascular/RPE abnormalities 42149122May. In metabolic dysfunction-associated steatohepatitis, the SIRT3-DsbA-L-TFAM axis was identified as a suppressor of mitochondrial stress-induced cGAS activation in hepatocytes, with loss of SIRT3 or DsbA-L promoting mtDNA release and worsening disease, whereas cGAS knockout or DsbA-L overexpression mitigated progression 42082480May.

A substantial portion of the recent literature used cGAS-STING activation as an immunostimulatory strategy in cancer. Biomaterial platforms delivered dsDNA, manganese, zinc, or other stimuli to amplify cGAS sensing and STING signaling in dendritic cells, macrophages, and tumor cells. Examples include a dsDNA-loaded manganese phosphate nanoadjuvant that enhanced cGAS recognition and robustly activated cGAS-STING in dendritic cells, promoting BMDC maturation and M1 polarization 42066000May; a photothermally programmable bacterial-metal immune amplifier in which Mn2+ lowered the cGAS activation threshold to hyper-activate STING and support dendritic cell maturation and CD8+ T-cell recruitment 42029112Apr; and a nanoparticle immunomodulator that coupled immunogenic cell death with Mn2+/Zn2+-mediated cGAS-STING activation to drive T-cell infiltration, tumor regression, and reduced metastasis/recurrence in breast cancer 41962772Apr. Similar cGAS-STING-dependent antitumor effects were reported for a Pt(IV) prodrug nanoparticle that combined DNA-repair inhibition with enhanced cGAS activity in nasopharyngeal carcinoma 41966338Apr, Salmonella biomimetic nanorobots that increased cytosolic dsDNA and released Mn2+ to activate cGAS-STING in colorectal cancer 41956144Apr, and composite nanovesicles that integrated chemodynamic therapy, decitabine-mediated epigenetic reactivation, and Mn2+-sensitized cGAS-STING signaling 41871782Mar.

Other studies highlighted cGAS-STING as a downstream effector of DNA damage, mitochondrial stress, and cell death programs. In esophageal squamous cell carcinoma, palbociclib-induced DNA damage and unprotected micronuclei enriched for cGAS were linked to interferon-stimulated gene activation and increased immune cell infiltration in delayed responders 42215475May. In cervical cancer, copper nanoassemblies triggered cuproptosis and mitochondrial DNA leakage, which then activated the cGAS-STING-IRF3 pathway 42044237Apr. A programmable DNAzyme nanocatalyst induced mitochondrial dysfunction and mtDNA release to activate cGAS-STING and create a transient redox sensitization window that improved checkpoint blockade responses 41981590Apr. In vitiligo-associated fibroblast activation, oxidative stress caused VDAC1-dependent mtDNA release that activated cGAS-STING and the NLRP3 inflammasome, linking redox imbalance to innate immune signaling 41722540Feb. Finally, AXL kinase inhibition was shown to relieve AKT-dependent suppression of cGAS, increase cGAMP and interferon signaling, and sensitize poorly immunogenic tumors to chemo-immunotherapy 41263056Nov.

Recent work also extended cGAS-STING biology to neuroinflammation and hemorrhagic injury. In intraventricular hemorrhage, dsDNA released from pyroptotic neurons and impaired mitochondrial autophagy in microglia were proposed to fuel sustained cGAS-STING activation, and pharmacological inhibition or conditional knockout of cGAS reduced neuroinflammation, microglial activation, and long-term hydrocephalus-related deficits 42050115Apr. Together, these studies reinforce the pathway’s dual role as a disease driver in sterile inflammation and a therapeutic amplifier when strategically engaged in cancer immunotherapy.

What Changes, What Holds

1. cGAS-STING is now implicated as a modifiable driver in several sterile inflammatory diseases beyond infection sensing
NEW DIRECTION Recent work extends the pathway from a general innate immune sensor to a therapeutic node in autoimmune, retinal, and metabolic liver disease, where dampening cGAS-STING appears to reduce tissue injury and inflammation 42268702Jun42149122May42082480May. That does not displace the established role in cytosolic DNA sensing; it broadens the disease contexts in which pathway inhibition may be useful and suggests mitochondrial stress and DNA repair defects are important upstream triggers in noninfectious settings.

2. cGAS-STING can be deliberately amplified as an antitumor strategy with biomaterial delivery systems
REINFORCES These studies strengthen, rather than revise, the baseline view that cGAS-STING is a promising cancer-immunotherapy target 42066000May42029112Apr. The new work mainly shows how to push the same axis harder and more selectively in tumors and antigen-presenting cells, using metals, dsDNA, and nanoplatforms to improve immune activation. The conceptual takeaway is practical: the pathway remains a valid immunostimulatory lever, and delivery chemistry is becoming central to how it is exploited.

3. DNA damage, mitochondrial injury, and cell death are emerging as common upstream routes into cGAS-STING signaling
NEW DIRECTION The Overview already places cytosolic DNA at the center of activation, but these findings specify how that DNA often appears in disease: micronuclei, mtDNA leakage, and stress-linked organelle failure can all feed the pathway 42215475May42044237Apr41981590Apr. That widens the mechanistic frame from pathogen or generic host DNA to damage biology, while also showing that cGAS-STING can mediate both treatment response and inflammatory bystander effects depending on context.

4. cGAS-STING inhibition may be neuroprotective in hemorrhagic injury
NEW DIRECTION Work in intraventricular hemorrhage adds a new disease setting not covered by the baseline, which focuses on innate immunity and cancer rather than brain injury 42050115Apr. The implication is that sustained cGAS-STING activation can worsen secondary neuroinflammation and hydrocephalus-related outcomes after sterile CNS damage, making pathway blockade a plausible adjunct in acute neurologic injury. This is an extension of the same biology, not a contradiction, but it strengthens the case that the pathway is broadly pathogenic when chronically engaged.

Overview update candidates: sterile inflammatory disease indications for cGAS-STING inhibition; mitochondrial stress; micronuclei; and mtDNA leakage as major upstream triggers; neuroinflammatory injury as a new therapeutic context.